A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus

Journal of Drugs in Dermatology

Volumn 7, Issue 12, 2008, Pages 1169-1171

  Reytan, Natalie ^a   Rzany, Berthold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CROSS LINKING REAGENT; RIBOSE;

ARTICLE; CASE REPORT; CHEMISTRY; ESTHETIC SURGERY; FACE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRADERMAL DRUG ADMINISTRATION; MALE; MENTAL STRESS; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COLLAGEN; COSMETIC TECHNIQUES; CROSS-LINKING REAGENTS; FACE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; RIBOSE; STRESS, PSYCHOLOGICAL;

EID: 60549101409     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Carr A, Samaras K, Thorisdotti tir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099. (Pubitemid 29278477)
2. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. Aids. 2001;15:2441-2444. (Pubitemid 34014613)
3. Yki-Jarvinen H, Sutinen J, Silveira A, et al. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol. 2003;23:688-694. (Pubitemid 36438085)
4. Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized doubleblind placebo-controlled study. Antivir Ther. 2003;8:199-207. (Pubitemid 36960893)
5. Sutinen J, Kannisto K, Korsheninnikova E, et al. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab. 2004;286:E941-949.
6. Lafeuillade A, Clumeck N, Mallolas J, et al. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study. HIV Clin Trials. 2003;4:37-43. (Pubitemid 36336096)
7. John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48- week study of switching stavudine and/or protease inhibitors to combivir/ abacavir to prevent or reverse lipoatrophy in HIV infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33. (Pubitemid 36547238)
8. Hatano H, Miller KD, Yoder CP, et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. Aids. 2000;14:1935-1942.
9. Koutkia P, Canavan B, Breu J, et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA. 2004;292:210-218. (Pubitemid 38917998)
10. Levan P, Nguyen TH, Lallemand F, et al. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. Aids. 2002;16:1985-1987.
11. Strauch B, Baum T, Robbins N. Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area. Plast Reconstr Surg. 2004;113:363-370. (Pubitemid 39202055)
12. Orentreich D, Leone AS. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone. Dermatol Surg. 2004;30:548-551. (Pubitemid 38529599)
13. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. Aids. 2003;17:2471-2477. (Pubitemid 38393319)
14. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004;5:82-87. (Pubitemid 38404660)
15. Cheonis N. New-Fill to treat facial wasting. Beta. 2002;15:10-15.
16. Onesti MG, Renzi LF, Paoletti F. Use of polylactic acid in face lipodystrophy in HIV positive patients undergoing treatment with antiretroviral drugs (HAART). Acta Chir Plast. 2004;46:12-15. (Pubitemid 38735908)
17. Walther RA. Facial lipodystrophy in patients with HIV infections troublesome to treat [in Swedish]. Lakartidningen. 2002;99:3826-3829.
18. Tzikas TL. Evaluation of the Radiance FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg. 2004;6:234-239.
19. James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg. 2002;28:979-986. (Pubitemid 35424794)
20. Protopapa C, Sito G, Caporale D, Cammarota N. Bio-Alcamid in drug induced lipodystrophy. J Cosmet Laser Ther. 2003;5:226-230.
21. Strand A, Wolters M. HIV-related lipodystrophy and facial lipatrophy: the role of Restylane SubQ in reversing facial wasting. Aesthetic Surg J. 2006; 26 (Suppl): S35-40.
22. Zielke H, Wölber L, Wiest L, Rzany B. Risk profiles of different injectable fillers: results from the Injectable Filler Safety Study (IFS Study) Dermatol Surg. 2008;34:326-335. (Pubitemid 351316823)
23. Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, openlabel, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg. 2006;118 (Suppl):34S-45.
24. Monstrey SJ, Pitaru S, Hamdi M, et al. A two-stage phase I trial of Evolence30 collagen for soft tissue contour correction. Plast Reconstr Surg. 2007;120:303-311. (Pubitemid 46956067)